{
    "organizations": [],
    "uuid": "9762fe3de7c69e75c1de9fbd28083910cf944e3f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biocartis-immunexpress-partnership/brief-biocartis-immunexpress-partnership-for-a-sepsis-host-immune-response-test-idUSFWN1PI1DV",
    "ord_in_thread": 0,
    "title": "BRIEF-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - BIOCARTIS GROUP NV:\n* BIOCARTIS & IMMUNEXPRESS SIGN PARTNERSHIP FOR A SEPSIS HOST IMMUNE RESPONSE TEST ON THE IDYLLA™ PLATFORM\n* AGREEMENT TO DEVELOP, COMMERCIALIZE OF IMMUNEXPRESS’ SEPTICYPTE TEST FOR USE ON CO‘S SAMPLETO-RESULT IDYLLA PLATFORM‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-24T14:50:00.000+02:00",
    "crawled": "2018-01-25T13:15:59.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "biocartis",
        "group",
        "nv",
        "biocartis",
        "immunexpress",
        "sign",
        "partnership",
        "sepsis",
        "host",
        "immune",
        "response",
        "test",
        "platform",
        "agreement",
        "develop",
        "commercialize",
        "immunexpress",
        "septicypte",
        "test",
        "use",
        "co",
        "idylla",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}